Abvc BiopharmaABVC
13F holders, Q1 2026 (March 31)13holders −1
4new positions
6sold out
1famous investor
$0.97avg. 13F price*
At the end of Q1 2026, 13 institutions reported holding Abvc Biopharma Inc. (ABVC) in their 13F filings, down 1 from Q4 2025. 4 opened new positions and 6 sold out. The largest holders were Geode Capital Management, LLC ($215K), Vanguard Capital Management LLC ($185K) and Vanguard Fiduciary Trust Co. ($94K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Abvc Biopharma Inc.
- CUSIP
- 00091F304
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $42K |
| Exits | 6 | $177K |
All 13F filers, Q4 2025 → Q1 2026: 64,848 shares bought and 103,211 shares sold, net −38,363 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 13 holders
| Geode Capital Management, LLC | 0.00% | Add +9.3% | 221,169 | $215K |
| Vanguard Capital Management LLC | 0.00% | — | 190,574 | $185K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 97,363 | $94K |
| Renaissance Technologies | 0.00% | Reduce -16.8% | 95,100 | $92K |
| State Street Corp. | 0.00% | No change | 72,800 | $71K |
| BlackRock, Inc. | 0.00% | No change | 56,442 | $55K |
| Northern Trust Corp. | 0.00% | No change | 32,087 | $31K |
| Two Sigma Securities, LLC | 0.00% | New | 21,023 | $20K |
| Dimensional Fund Advisors LP | 0.00% | New | 12,227 | $12K |
| Squarepoint Ops LLC | 0.00% | New | 10,547 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +69.8% | 5,423 | $5K |
| UBS Group AG | 0.00% | Reduce -31.6% | 1,771 | $2K |
| Royal Bank of Canada | 0.00% | New | 17 | $0 |
"% of holder's portfolio" is ABVC's weight in each manager's 13F, not the share of Abvc Biopharma Inc. the manager owns.